Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
FDA Approves Enbumyst (bumetanide) Nasal Spray for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
HENDERSON, Nev.--(BUSINESS WIRE) September 15, 2025 --Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient...
Parental Diseases of Despair Linked to Suicidal Events in Offspring
MONDAY, Sept. 15, 2025 -- Parental diseases of despair (DoD; i.e., substance use disorder, alcohol-related disease, or suicidal behavior) are associated with...
Childhood Loneliness Linked to Cognitive Decline in Adulthood
MONDAY, Sept. 16, 2025 -- Childhood loneliness is associated with cognitive decline and dementia risk in adulthood, according to a study published online Sept...
Globally, Diabetes Underdiagnosed, Poorly Controlled With Treatment
MONDAY, Sept. 15, 2025 -- In 2023, 55.8 percent of those with diabetes were diagnosed, and 41.6 percent had optimal glycemic concentrations on treatment...
Methotrexate Cuts Systolic BP in Rheumatoid Arthritis
MONDAY, Sept. 15, 2025 -- For patients with rheumatoid arthritis (RA), methotrexate significantly reduces systolic blood pressure (SBP), according to a study...
2016 to 2023 Saw Decline in U.S. Pediatric Radiologists
MONDAY, Sept. 15, 2025 -- The number of U.S. pediatric radiologists declined from 2016 to 2023, according to a study published online Sept. 9 in the Journal of...
California Votes To Ban PFAS ‘Forever Chemicals’ in Cookware, Other Items
MONDAY, Sept. 15, 2025 — Every time you reach for a nonstick pan, you could be using chemicals that are now on the chopping block in the state of...
Child in Los Angeles Dies of Rare Brain Disorder Caused by Measles
MONDAY, Sept. 15, 2025 — A child in Los Angeles County has died from a rare brain disorder caused by a measles infection in infancy, health officials...
Recall: Bariatric Fusion Vitamins Pulled for Missing Child-Safe Caps
MONDAY, Sept. 15, 2025 — About 4,700 bottles of Bariatric Fusion iron-containing multivitamins have been recalled because packaging does not meet federal...
Ebola Vaccinations Begin in Congo After Deadly Outbreak
MONDAY, Sept. 15, 2025 — Health workers in southern Kasai province have started giving Ebola vaccines as officials race to contain the latest outbreak...
Smoking Increases Risk Of Type 2 Diabetes
MONDAY, Sept. 15, 2025 — Smokers have a higher risk of developing type 2 diabetes, especially if they are genetically predisposed to the condition, a new...
FDA Approves Selumetinib for Pediatric Patients 1 year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas
On September 10, 2025, the Food and Drug Administration approved selumetinib (Koselugo, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric...
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 10, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery...
FDA Approves Inlexzo (gemcitabine intravesical system) for the Treatment of Non-Muscle Invasive Bladder Cancer
September 9, 2025. RARITAN, N.J., September 9, 2025 /PRNewswire/ – Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration...
U.S. FDA Approves Expanded Indication for Vonvendi [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 5, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration...
FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB...
Stealth Biotherapeutics Announces FDA Acceptance of Elamipretide NDA Resubmission
NEEDHAM, Mass., Aug. 21, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and...
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a...
Stealth Biotherapeutics Resubmits New Drug Application for Elamipretide for the Treatment of Barth Syndrome
NEEDHAM, Mass., Aug. 18, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development...
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company...
Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial
30 August 2025 -- Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful r...
Regeneron Announces Positive Results from Phase 3 Trial of Cemdisiran in Generalized Myasthenia Gravis
TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key secondary endpoints...
Lilly's Oral GLP-1, Orforglipron, is Successful in Third Phase 3 Trial, Triggering Global Regulatory Submissions This Year for the Treatment of Obesity
INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial...
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") announced today that rusfertide, a potential...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.